Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

Davies MJ, Bajaj HS, Broholm C, Eliasen A, Garvey WT, le Roux CW, Lingvay I, Lyndgaard CB, Rosenstock J, Pedersen SD

The New England journal of medicine22 Jun 2025Cited by 77 (Europe PMC)

PMID40544432DOI10.1056/nejmoa2502082PepBankPUB-40544432

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone14

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and type 2 diabetes, cagrilintide-semaglutide reduced body weight by 13.7% versus 3.4% with placebo at week 68.
In plain wordsIn adults with obesity and type 2 diabetes, cagrilintide with semaglutide cut body weight by 13.7% over 68 weeks, compared with 3.4% with placebo.
Peptide
Cagrilintide
Outcome
DecreasePercent change in body weight at week 68
Study
n = 1,206
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Mean change in body weight
−13.7%
cagrilintide-semaglutide
Mean change in body weight
−3.4%
placebo
Estimated difference
−10.4 percentage points
cagrilintide-semaglutide vs placebo
Source sentences
Summary
The estimated mean change in body weight from baseline to week 68 was -13.7% in the cagrilintide-semaglutide group and -3.4% in the placebo group (estimated difference, -10.4 percentage points; 95% confidence interval, -11.2 to -9.5; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443201
02HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and type 2 diabetes, more patients on cagrilintide-semaglutide than on placebo had a weight reduction of 5% or more.
In plain wordsIn adults with obesity and type 2 diabetes, more people on cagrilintide with semaglutide lost 5% or more of body weight than on placebo.
Peptide
Cagrilintide
Outcome
IncreaseWeight reduction of 5% or more
Study
n = 1,206
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443202
03HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity and type 2 diabetes, once-weekly cagrilintide-semaglutide (CagriSema) lowered body weight by 13.7% versus 3.4% with placebo at week 68.
In plain wordsIn adults with obesity and type 2 diabetes, the CagriSema combination reduced body weight more than placebo over 68 weeks.
Peptide
Semaglutide
Outcome
DecreaseBody weight percent change at week 68
Study
n = 1,206
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
body weight change
−13.7%
cagrilintide-semaglutide
body weight change
−3.4%
placebo
estimated difference
−10.4 percentage points
cagrilintide-semaglutide versus placebo
Source sentences
Summary
The estimated mean change in body weight from baseline to week 68 was -13.7% in the cagrilintide-semaglutide group and -3.4% in the placebo group (estimated difference, -10.4 percentage points; 95% confidence interval, -11.2 to -9.5; P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443208
04HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity and type 2 diabetes, more patients on CagriSema than on placebo had a weight reduction of 5% or more.
In plain wordsIn adults with obesity and type 2 diabetes, more people on the CagriSema combination than on placebo lost at least 5% of body weight.
Peptide
Semaglutide
Outcome
IncreaseWeight reduction of at least 5%
Study
n = 1,206
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was true of reductions of at least 10%, 15%, and 20% (P<0.001 for the last comparison).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443209
05HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and type 2 diabetes, more patients on cagrilintide-semaglutide than on placebo had a weight reduction of at least 10%.
In plain wordsIn adults with obesity and type 2 diabetes, more people on cagrilintide with semaglutide lost at least 10% of body weight than on placebo.
Peptide
Cagrilintide
Outcome
IncreaseWeight reduction of at least 10%
Study
n = 1,206
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was true of reductions of at least 10%, 15%, and 20% (P<0.001 for the last comparison).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443203
06HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and type 2 diabetes, more patients on cagrilintide-semaglutide than on placebo had a weight reduction of at least 15%.
In plain wordsIn adults with obesity and type 2 diabetes, more people on cagrilintide with semaglutide lost at least 15% of body weight than on placebo.
Peptide
Cagrilintide
Outcome
IncreaseWeight reduction of at least 15%
Study
n = 1,206
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was true of reductions of at least 10%, 15%, and 20% (P<0.001 for the last comparison).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443204
07HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and type 2 diabetes, more patients on cagrilintide-semaglutide than on placebo had a weight reduction of at least 20%.
In plain wordsIn adults with obesity and type 2 diabetes, more people on cagrilintide with semaglutide lost at least 20% of body weight than on placebo.
Peptide
Cagrilintide
Outcome
IncreaseWeight reduction of at least 20%
Study
n = 1,206
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was true of reductions of at least 10%, 15%, and 20% (P<0.001 for the last comparison).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443205
08HumanNot a test of Cagrilintide aloneRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and type 2 diabetes, 73.5% on cagrilintide-semaglutide reached a glycated hemoglobin of 6.5% or less versus 15.9% on placebo.
In plain wordsIn adults with obesity and type 2 diabetes, 73.5% on cagrilintide with semaglutide reached an HbA1c of 6.5% or less, compared with 15.9% on placebo.
Peptide
Cagrilintide
Outcome
IncreaseGlycated hemoglobin 6.5% or less
Study
n = 1,206
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
Patients with HbA1c 6.5% or less
73.5%
cagrilintide-semaglutide
Patients with HbA1c 6.5% or less
15.9%
placebo
Source sentences
Summary
The percentage of patients who had a glycated hemoglobin level of 6.5% or less was 73.5% in the cagrilintide-semaglutide group and 15.9% in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443206
09HumanNot a test of Cagrilintide aloneRandomized controlled trialSafety outcome
In adults with overweight or obesity and type 2 diabetes, gastrointestinal adverse events occurred in 72.5% on cagrilintide-semaglutide versus 34.4% on placebo, mostly transient and mild or moderate.
In plain wordsIn adults with obesity and diabetes, stomach and bowel side effects were more common with cagrilintide plus semaglutide than with placebo, mostly mild.
Peptide
Cagrilintide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 1,206
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Gastrointestinal adverse events
72.5%
cagrilintide-semaglutide
Gastrointestinal adverse events
34.4%
placebo
Source sentences
Summary
Gastrointestinal adverse events were reported by 72.5% of the patients in the cagrilintide-semaglutide group and 34.4% in the placebo group, most of which were transient and mild or moderate in severity.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4054443207
10HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity and type 2 diabetes, more patients on CagriSema than on placebo had a weight reduction of 10% or more.
In plain wordsIn adults with obesity and type 2 diabetes, more people on the CagriSema combination than on placebo lost at least 10% of body weight.
Peptide
Semaglutide
Outcome
IncreaseWeight reduction of at least 10%
Study
n = 1,206
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was true of reductions of at least 10%, 15%, and 20% (P<0.001 for the last comparison).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443210
11HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity and type 2 diabetes, more patients on CagriSema than on placebo had a weight reduction of 15% or more.
In plain wordsIn adults with obesity and type 2 diabetes, more people on the CagriSema combination than on placebo lost at least 15% of body weight.
Peptide
Semaglutide
Outcome
IncreaseWeight reduction of at least 15%
Study
n = 1,206
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was true of reductions of at least 10%, 15%, and 20% (P<0.001 for the last comparison).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443211
12HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity and type 2 diabetes, more patients on CagriSema than on placebo had a weight reduction of 20% or more.
In plain wordsIn adults with obesity and type 2 diabetes, more people on the CagriSema combination than on placebo lost at least 20% of body weight.
Peptide
Semaglutide
Outcome
IncreaseWeight reduction of at least 20%
Study
n = 1,206
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
More patients in the cagrilintide-semaglutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was true of reductions of at least 10%, 15%, and 20% (P<0.001 for the last comparison).
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443212
13HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome
In adults with obesity and type 2 diabetes, 73.5% on CagriSema reached HbA1c of 6.5% or less versus 15.9% on placebo.
In plain wordsIn adults with obesity and type 2 diabetes, far more people on the CagriSema combination than on placebo reached an HbA1c of 6.5% or less.
Peptide
Semaglutide
Outcome
IncreaseHbA1c of 6.5% or less
Study
n = 1,206
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
proportion with HbA1c <=6.5%
73.5%
cagrilintide-semaglutide
proportion with HbA1c <=6.5%
15.9%
placebo
Source sentences
Summary
The percentage of patients who had a glycated hemoglobin level of 6.5% or less was 73.5% in the cagrilintide-semaglutide group and 15.9% in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443213
14HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome
In adults with obesity and type 2 diabetes, gastrointestinal adverse events occurred in 72.5% on CagriSema versus 34.4% on placebo, mostly transient and mild or moderate.
In plain wordsIn adults with obesity and type 2 diabetes, stomach and gut side effects were more common with the CagriSema combination than with placebo.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 1,206
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
GI adverse events
72.5%
cagrilintide-semaglutide
GI adverse events
34.4%
placebo
Source sentences
Summary
Gastrointestinal adverse events were reported by 72.5% of the patients in the cagrilintide-semaglutide group and 34.4% in the placebo group, most of which were transient and mild or moderate in severity.
1 context sentence(design, population, supporting numbers)
Summary · context
In this phase 3a, double-blind, randomized, placebo-controlled trial conducted in 12 countries, we assigned adults with a body-mass index of 27 or more, a glycated hemoglobin level of 7 to 10%, and type 2 diabetes in a 3:1 ratio to receive once-weekly cagrilintide-semaglutide (2.4 mg each) or placeb…
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4054443214

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT05394519

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Novo Nordisk A/Sn = 1,2001 Feb 2023 to 3 Feb 2025

Overweight · Obesity · Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 28 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC